This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by DeGrado, T. R. Articles by Price, D. T. Search for Related Content PubMed Articles by DeGrado, T. R. Articles by Price, D. T.

Synthesis and Evaluation of ¹⁸F-labeled Choline as an Oncologic Tracer for Positron Emission Tomography: Initial Findings in Prostate Cancer

Departments of Radiology [T. R. D., R. E. C., S. W.] and Surgery [C. N. R., T. J. P., D. T. P.], Duke University Medical Center, Durham, North Carolina 27710, and Department of Chemistry, Duke University, Durham, North Carolina 27708 [S. W. B., M. D. O.]

The up-regulation of rates of choline uptake and phosphorylation in certain malignancies has motivated the development of positron-labeled choline analogues for noninvasive detection of cancer using positron emission tomography (PET). The choline analogue, no-carrier-added [¹⁸F]fluoromethyl-dimethyl-2-hydroxyethyl-ammonium (FCH), was synthesized through the intermediate [¹⁸F]fluorobromomethane. FCH was evaluated in relationship to 2-[¹⁸F]fluoro-2-deoxyglucose (FDG) as an oncological probe in cultured PC-3 human prostate cancer cells, a murine PC-3 human prostate cancer xenograft model, and in PET imaging studies of patients with prostate cancer. FCH was synthesized in 20–40% radiochemical yield and >98% radiochemical purity. Accumulation of FCH and FDG were comparable in cultured prostate cancer cells, whereas only FCH was inhibited (90%) by hemicholinium-3, a specific inhibitor of choline transport and phosphorylation. FCH showed similar biodistribution to [¹⁴C]choline in the tumor-bearing mouse, with prominent renal and hepatic uptake. Tumor uptake of FCH was similar to choline and FDG in the mouse model, although tumor:blood ratios were moderately higher for FCH. Initial PET imaging studies in prostate cancer patients showed high uptake of FCH in advanced prostate carcinoma and detection of osseous and soft tissue metastases. FCH uptake by tumors was markedly reduced in patients rescanned during androgen deprivation therapy. It is concluded that FCH closely mimics choline uptake by normal tissues and prostate cancer neoplasms. FCH is potentially useful as a PET tracer for detection and localization of prostate cancer and monitoring effects of therapy.

This article has been cited by other articles:

				R. M. Pieterman, T. H. Que, P. H. Elsinga, J. Pruim, J. W.G. van Putten, A. T.M. Willemsen, W. Vaalburg, and H. J.M. Groen Comparison of 11C-Choline and 18F-FDG PET in Primary Diagnosis and Staging of Patients with Thoracic Cancer J. Nucl. Med., February 1, 2002; 43(2): 167 - 172. [Abstract] [Full Text] [PDF]

				T. Hara, N. Kosaka, and H. Kishi Development of 18F-Fluoroethylcholine for Cancer Imaging with PET: Synthesis, Biochemistry, and Prostate Cancer Imaging J. Nucl. Med., February 1, 2002; 43(2): 187 - 199. [Abstract] [Full Text] [PDF]

				J. Kotzerke, J. E. Gschwend, and B. Neumaier PET for Prostate Cancer Imaging: Still a Quandary or the Ultimate Solution? J. Nucl. Med., February 1, 2002; 43(2): 200 - 202. [Full Text] [PDF]

				T. R. DeGrado, R. E. Reiman, D. T. Price, S. Wang, and R. E. Coleman Pharmacokinetics and Radiation Dosimetry of 18F-Fluorocholine J. Nucl. Med., January 1, 2002; 43(1): 92 - 96. [Abstract] [Full Text] [PDF]

				T. R. DeGrado, S. W. Baldwin, S. Wang, M. D. Orr, R. P. Liao, H. S. Friedman, R. Reiman, D. T. Price, and R. E. Coleman Synthesis and Evaluation of 18F-Labeled Choline Analogs as Oncologic PET Tracers J. Nucl. Med., December 1, 2001; 42(12): 1805 - 1814. [Abstract] [Full Text] [PDF]

				T. Hara 18F-Fluorocholine: A New Oncologic PET Tracer J. Nucl. Med., December 1, 2001; 42(12): 1815 - 1817. [Full Text] [PDF]